1-(benzyloxycarbonyl)indol-3-yl acetic acid | 187244-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(benzyloxycarbonyl)indol-3-yl acetic acid
• 英文别名: 2-(1-phenylmethoxycarbonylindol-3-yl)acetic acid
• CAS: 187244-70-8
• 化学式: C₁₈H₁₅NO₄
• 分子量: 309.321
• InChiKey: QVFNCAMVGRMVAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(benzyloxycarbonyl)indol-3-yl acetic acid 在 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 乙醚 、 丙酮 为溶剂， 反应 1.0h， 生成 benzyl 3-(3-acetoxy-2-oxopropyl)-1H-indole-1-carboxylate
  参考文献：
  名称：

  2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic Acid (PSI-697):  Identification of a Clinical Candidate from the Quinoline Salicylic Acid Series of P-Selectin Antagonists

  摘要：

  P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.

  DOI：

  10.1021/jm060631p
• 作为产物：
  描述：

  氯甲酸苄酯 在 lithium hexamethyldisilazane 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 以98%的产率得到1-(benzyloxycarbonyl)indol-3-yl acetic acid
  参考文献：
  名称：

  Methods and compositions for selectin inhibition

  摘要：

  本发明涉及抗炎物质领域，更特别地涉及作为哺乳动物粘附蛋白拮抗剂的新化合物。在某些实施例中，提供了治疗选择素介导疾病的方法，包括给予式I的化合物： 其中组分变量在此定义。

  公开号：

  US20050101569A1

文献信息

• Methods and Compositions for Treatment of Scleritis and Related Disorders
  申请人：Bedard Patricia W.

  公开号：US20080125454A1

  公开（公告）日：2008-05-29

  The present teachings relate to the field of anti-inflammatory substances and more particularly to compounds that are useful for the treatment of scleritis, a scleritis symptom, or a scleritis-related disorder. In one aspect, methods of treating scleritis, a scleritis symptom, or a scleritis-related disorder generally include administering to a subject a compound of Formula I: or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein W 1 , W 2 , R 1 , L, X, Y, Z, and n 1 are defined as described herein.

  目前的教导涉及抗炎物质领域，更具体地涉及对用于治疗巩膜炎、巩膜炎症状或与巩膜炎相关疾病有用的化合物。在一个方面，治疗巩膜炎、巩膜炎症状或巩膜炎相关疾病的方法通常包括向受试者施用公式I的化合物： 或其药用可接受的盐、水合物或酯，其中W 1 ，W 2 ，R 1 ，L，X，Y，Z和n 1 的定义如本文所述。
• Enantioselective Syntheses of <i>Strychnos</i> and <i>Chelidonium</i> Alkaloids through Regio‐ and Stereocontrolled Cooperative Catalysis
  作者：Luke S. Hutchings‐Goetz、Chao Yang、James W. B. Fyfe、Thomas N. Snaddon

  DOI：10.1002/anie.202005151

  日期：2020.9.28

  We describe enantioselective syntheses of strychnos and chelidonium alkaloids. In the first case, indole acetic acid esters were established as excellent partner nucleophiles for enantioselective cooperative isothiourea/Pd catalyzed α‐alkylation. This provides products containing indole‐bearing stereocenters in high yield and with excellent levels of enantioinduction in a manner that is notably independent

  我们描述的对映选择性合成马钱子和白屈菜生物碱。在第一种情况下，吲哚乙酸酯被确定为对映选择性协同异硫脲/ Pd催化α-烷基化的优秀伴侣亲核试剂。这提供了以高收率和出色的对映体诱导水平包含吲哚的立构中心的产品，其方式明显独立于N取代基。这导致了（−）‐ akuammicine和（−）‐ strychnine的简明合成。在第二种情况下，邻位表现不佳对映选择性协同异硫脲/ Ir催化的α-烷基化反应中的预取代肉桂酸亲电试剂可通过适当的取代基选择来克服，从而导致（+）-螯合碱，（+）-去甲螯合碱和（+）-螯合胺的对映选择性合成。
• Diastereoselective Cationic Tandem Cyclizations to <i>N</i>-Heterocyclic Scaffolds:  Total Synthesis of (−)-Dysibetaine PP
  作者：Denis R. IJzendoorn、Peter N. M. Botman、Richard H. Blaauw

  DOI：10.1021/ol052598r

  日期：2006.1.1

  [reaction: see text] Herein, we report a short and diastereoselective synthesis of the natural product (-)-dysibetaine PP. The key step in the synthetic sequence is a novel highly diastereoselective tandem-cyclization reaction of an enantiomerically pure dipeptide. This cyclization methodology is applied in the synthesis of a broader range of N-heterocyclic scaffolds.

  [反应：见正文]在此，我们报道了天然产物（-）-dysibetaine PP的短而非对映选择性合成。合成序列中的关键步骤是对映体纯的二肽的新型高度非对映选择性串联环化反应。这种环化方法学可用于合成范围更广的N杂环支架。
• Enantioselective synthesis of 2-substituted 3-aminopropanoic acid (β-alanine) derivatives which are β-analogues of aromatic amino acids
  作者：Elena Arvanitis、Holger Ernst、Alice A. LudwigéD’Souza、Andrew J. Robinson、Peter B. Wyatt

  DOI：10.1039/a706163c

  日期：——

  3-Aminopropanoic acid derivatives with a phenyl, 4-hydroxyphenyl, benzyl or indol-3-yl substituent at C-2 can be prepared enantioselectively by routes involving electrophilic attack of synthetic equivalents of [H2NCH2]+ upon enolates derived from chiral 3-acyl-1,3-oxazolidin-2-ones. tert-Butyl bromoacetate may be used as the electrophile, with subsequent introduction of nitrogen through the Curtius reaction, using the sequence of reagents (i) CF3CO2H; (ii) (PhO)2P(O)N3, Et3N, PhCH2OH; alternatively, direct electrophilic reaction with 1-[N-(benzyloxycarbonyl)aminomethyl]benzotriazole 4c or benzyl N-(acetoxymethyl)carbamate 2d introduces a protected aminomethyl group in a single step.

  具有苯基、4-羟基苯基、苄基或吲哚-3-基的C-2取代基的3-氨基丙酸衍生物可以通过涉及合成[H2NCH2]+的亲电攻击的路线，从手性3-酰基-1,3-恶唑烷-2-酮衍生的烯醇盐选择性地制备。可以使用叔丁基溴乙酸酯作为亲电试剂，随后通过Curtius反应引入氮，使用试剂序列（i）CF3CO2H；（ii）(PhO)2P(O)N3，Et3N，PhCH2OH；或者，直接与1-[N-(苄氧羰基)氨基甲基]苯并三唑4c或苄基N-(乙酸甲酯)氨基甲酸酯2d进行亲电反应，一步引入保护的氨基甲基基团。
• Methods and Compositions for Selectin Inhibition
  申请人：Kaila Neelu

  公开号：US20090069564A1

  公开（公告）日：2009-03-12

  The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: wherein the constituent variables are defined herein.

  本发明涉及抗炎物质领域，更具体地涉及一种新型化合物，其作为哺乳动物粘附蛋白选择素的拮抗剂。在某些实施例中，提供了治疗选择素介导疾病的方法，其中包括给予式I化合物的治疗，其中该式中的组分变量在此定义。